Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

Ana Oaknin, Laurence Gladieff, Jerónimo Martínez-García, +116

The Lancet

OncologyCervical CancerMetronomic TherapyPathologyRecurrent Cervical Cancer +4

Metastatic breast cancer subtypes and central nervous system metastases

Caterina Aversa, V. Rossi, Elena Geuna, +6

The Breast

A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies

Dejan Juric, Johann S. de Bono, Patricia LoRusso, +13

Clinical Cancer Research

The neutrophil–lymphocyte ratio and its utilisation for the management of cancer patients in early clinical trials

Rajiv Kumar, Elena Geuna, Vasiliki Michalarea, +5

British Journal of Cancer

Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases

Giulia Siravegna, Elena Geuna, Benedetta Mussolin, +9

ESMO Open

Self‐evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study

Danilo Galizia, Andrea Milani, Elena Geuna, +16

Cancer Medicine

Higher Risk of Infections with PI3K–AKT–mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials

Saeed Rafii, Desamparados Roda, Elena Geuna, +8

Clinical Cancer Research

Circulating Cytokines in Metastatic Breast Cancer Patients Select Different Prognostic Groups and Patients Who Might Benefit from Treatment beyond Progression

Matteo Paccagnella, Andrea Abbona, Andrea Michelotti, +9

Vaccines

Breast OncologyImmunologyImmunoeditingPathologyImmunotherapeutics +17

Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition

Federica Verginelli, Alberto Pisacane, Gennaro Gambardella, +14

Nature Communications

Complications of hyperglycaemia with PI3K–AKT–mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials

Elena Geuna, Desamparados Roda, Saeed Rafii, +9

British Journal of Cancer